CytomX Therapeutics CTMX
NASDAQ CTMX
$2.75 +0.06 (+2.23%)
At close: Sep 29, 2026 · 4:00 PM EDT

CytomX Therapeutics (CTMX) EBIT Margin (2014 - 2026)

Updated

CytomX Therapeutics' EBIT Margin came in at -1677.08% for Q2 2026, down 1670.19 percentage points from -6.89% a year earlier and down 1485.31 percentage points from the prior quarter.

Analysis

CytomX Therapeutics (CTMX) EBIT Margin (2014 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, CytomX Therapeutics reported EBIT Margin of -476.19%, down 506.76 percentage points year-over-year; for FY2025, it was -29.35%, down 47.45 percentage points from FY2024.

  • EBIT Margin carries a five-year change of +88.35 percentage points (FY2020 to FY2025).
  • Going back by year, EBIT Margin was 18.10% in FY2024 (+24.51 pp), -6.41% in FY2023 (+184.21 pp), -190.61% in FY2022 (+120.39 pp) and -311.00% in FY2021 (-193.30 pp).
  • The five-year range for quarterly EBIT Margin is -4212.97% (Q4 2025) to 46.41% (Q4 2024).
  • Year-over-year, EBIT Margin has declined for four consecutive quarters, with an average year-over-year change of -793.78 percentage points over the last eight quarters.
  • The fastest year-over-year change in EBIT Margin over five years came in Q1 2023 (a gain of 330.61 percentage points), and the weakest in Q4 2025 (a drop of 4259.38 percentage points).
  • Business Quant data shows CTMX's EBIT Margin at -191.77% (Q1 2026), -4212.97% (Q4 2025) and -264.43% (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 28.21%
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 37.86%
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn -3.52%
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 32.97%
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 20.57%
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 34.95%
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -133.21%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 28.37%
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 37.40%
10 CytomX Therapeutics 586.15 Mn -371.52 Mn - -1,677.08%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -1,677.08%
Mar 31, 2026 -191.77%
Dec 31, 2025 -4,212.97%
Sep 30, 2025 -264.43%
Jun 30, 2025 -6.89%
Mar 31, 2025 44.43%
Dec 31, 2024 46.41%
Sep 30, 2024 12.30%
Jun 30, 2024 -33.65%
Mar 31, 2024 28.11%
Dec 31, 2023 -2.28%
Sep 30, 2023 11.84%
Jun 30, 2023 -13.54%
Mar 31, 2023 -24.06%
Dec 31, 2022 -47.25%
Sep 30, 2022 -266.53%
Jun 30, 2022 -233.83%
Mar 31, 2022 -354.67%
Dec 31, 2021 -313.54%
Sep 30, 2021 -337.78%
API Access

CytomX Therapeutics EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=CTMX&period=max&api_key=YOUR_API_KEY